

# A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

NCT07096843

---

Status	RECRUITING
Phase	Phase 2
Sponsor	Climb Bio, Inc.
Enrollment	45 participants

## Key Eligibility Criteria

---

### Inclusion (8)

- Confirmed diagnosis of PMN with positive anti-PLA2R antibodies
- CD19+ B cell count  $\geq 40$  cells/ $\mu$ L
- UPCR  $\leq 2.0$  g/g
- eGFR  $\geq 40$  mL/min/1.73 m<sup>2</sup>
- Stable RAAS inhibitor therapy

... and 3 more (see full listing online)

### Exclusion (8)

- Secondary Membranous Nephropathy
- Rapidly progressive glomerulonephritis or other glomerulopathies
- Prior B cell-depleting therapy within 24 weeks
- Recent use of immunosuppressants
- Active or high-risk infections

... and 3 more (see full listing online)

## Locations (33 total)

---

Climb Bio Investigative Site #110, Denver, Colorado, United States  
Climb Bio Investigative Site #105, Orlando, Florida, United States  
Climb Bio Investigative Site #108, Atlanta, Georgia, United States  
... and 30 more locations